Free tool
Stocks near their 52-week high
We cover 72 companies trading within 5% of their own 52-week high. The median market value in the group is $5.73B. Across the group, the median move over the past trading day is 0.00%. 99% of the 71 with a 200-day average trade above it. Price change over the past year runs from +11.8% to +194.0% across the middle 80 percent of the group, with a median of +56.5%. Across the group, 3 companies currently carry a tier A volume signal.
Other lists in this group
Table
72 of 3,992 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| LLY.DE | Eli Lilly and Company | $1.07T | Mega cap | +73.55% |
| JNJ | Johnson & Johnson | $658.24B | Mega cap | +55.40% |
| JNJB34.SA | Johnson & Johnson | $658.09B | Mega cap | +47.82% |
| JNJ.DE | Johnson & Johnson | $651.71B | Mega cap | +58.93% |
| 4AB.DE | AbbVie Inc. | $471.29B | Mega cap | +32.34% |
| ABBV | AbbVie Inc. | $469.68B | Mega cap | +29.36% |
| ABBV34.SA | AbbVie Inc. | $467.00B | Mega cap | +21.88% |
| MRCK34.SA | Merck & Co., Inc. | $388.60B | Mega cap | +81.07% |
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% |
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | +86.85% |
| RHO.DE | Roche Holding AG | $370.84B | Mega cap | +41.42% |
| AMGN34.SA | Amgen Inc. | $239.09B | Mega cap | +47.79% |
| AMGN | Amgen Inc. | $238.06B | Mega cap | +56.24% |
| AMG.DE | Amgen Inc. | $237.76B | Mega cap | +60.12% |
| TMO | Thermo Fisher Scientific Inc. | $234.31B | Mega cap | +30.17% |
| TN8.DE | Thermo Fisher Scientific Inc. | $234.00B | Mega cap | +29.67% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +62.83% |
| BIO-B | Bio-Rad Laboratories, Inc. | $9.77B | Mid cap | +47.78% |
| TWST | Twist Bioscience Corporation | $9.41B | Mid cap | +451.89% |
| DEMANT.CO | Demant A/S | $9.36B | Mid cap | +17.12% |
| IMVT | Immunovant, Inc. | $9.07B | Mid cap | +189.13% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| HQY | HealthEquity, Inc. | $8.75B | Mid cap | +18.69% |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% |
| RHC.AX | Ramsay Health Care Limited | $8.27B | Mid cap | +50.11% |
| SRRK | Scholar Rock Holding Corporation | $7.31B | Mid cap | +74.18% |
| 6869.T | Sysmex Corporation | $7.28B | Mid cap | +3.66% |
| HNGE | Hinge Health, Inc. | $7.25B | Mid cap | +56.66% |
| CHE | Chemed Corporation | $7.11B | Mid cap | +20.79% |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% |
| E2XE34.SA | Exelixis, Inc. | $6.61B | Mid cap | +23.92% |
| HLUN-A.CO | H. Lundbeck A/S | $6.40B | Mid cap | +29.71% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +143.24% |
| TVTX | Travere Therapeutics, Inc. | $6.24B | Mid cap | +284.86% |
| TFX | Teleflex Incorporated | $5.88B | Mid cap | +8.06% |
| SHC | Sotera Health Company | $5.58B | Mid cap | +18.42% |
| MMSI | Merit Medical Systems, Inc. | $5.44B | Mid cap | −0.28% |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.07B | Mid cap | +11.33% |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +93.26% |
| HAE | Haemonetics Corporation | $4.85B | Mid cap | +93.71% |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% |
| CON | Concentra Group Holdings Parent, Inc. | $4.44B | Mid cap | +50.93% |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.84% |
| ADPT | Adaptive Biotechnologies Corporation | $4.18B | Mid cap | +101.70% |
| 1SXP.DE | SCHOTT Pharma AG & Co. KGaA | $4.08B | Mid cap | +1.26% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% |
| BBZA.DE | BB Biotech AG | $3.87B | Mid cap | +7.22% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
| OGN | Organon & Co. | $3.62B | Mid cap | +50.67% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% |
| AXGN | AxoGen, Inc. Common Stock | $2.68B | Mid cap | +219.58% |
| PGEN | Precigen, Inc. | $2.65B | Mid cap | +61.66% |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% |
| PHVS | Pharvaris N.V. | $2.60B | Mid cap | +55.59% |
| BV3.DE | Bavarian Nordic A/S | $2.55B | Mid cap | +15.65% |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.45B | Mid cap | +70.53% |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.31B | Mid cap | +4.23% |
| NEO | NeoGenomics, Inc. | $2.26B | Mid cap | +145.34% |
| ADUS | Addus HomeCare Corporation | $2.25B | Mid cap | +4.50% |
| PVLA | Palvella Therapeutics, Inc. | $2.22B | Mid cap | +173.39% |
| MD | Pediatrix Medical Group, Inc. | $2.19B | Mid cap | +56.87% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
| SEM | Select Medical Holdings Corp | $2.05B | Mid cap | +28.14% |
| 6960.T | Fukuda Denshi Co., Ltd. | $2.02B | Mid cap | +79.12% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.